Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Honest Company Inc (HNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Honest Company Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.34 (market cap $8.04B), while Honest Company Inc trades at $4.04 (market cap $435.91M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 18.4× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | HNST | |
|---|---|---|
Market Cap | $8.04B | $435.91M |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $4.95 |
52-Week Low | $241.71 | $2.10 |
Enterprise Value | $7.85B | $357.31M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
HNST trades at $3.90, down 2.74% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, while revenue trends show volatility with 2025 revenue at $371.32M. Gross margins improved to 33.89%, but net income remains negative at -$15.69M for 2025. Positive cash flow from operations of $15.12M supports liquidity, though profitability challenges persist.
Outlook is mixed: analyst consensus leans hold (50%) with 30% buy ratings, citing improved fundamentals but limited upside. Key risks include sustained negative net margins and competitive pressures in personal care. The stock's high P/E of 48.83 suggests premium valuation despite lack of profits, requiring careful risk assessment for investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
